COMMUNIQUÉS West-GlobeNewswire

Cytek Biosciences Announces $50 Million Stock Repurchase Program
06/06/2024
FREMONT, Calif., June 06, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced that its Board of Directors has approved the repurchase of up to an [...]
electroCore, Inc. Announces Closing of $9.3 Million Registered Direct Offering and Concurrent Private Placements Priced At Market Under Nasdaq Rules
06/06/2024
ROCKAWAY, N.J., June 06, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a commercial-stage bioelectronic medicine and wellness company, today announced the closing of its [...]
Ocuphire Pharma Announces Presentations on the Development of APX3330 for Diabetic Retinopathy at Retina Meetings in June
06/06/2024
FARMINGTON HILLS, Mich., June 06, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP) (“Ocuphire”), a clinical-stage biopharmaceutical company focused on developing small molecule therapies for the treatment [...]
OneMedNet Significantly Expands Industry Access to Proprietary iRWD™ Network and Platform by Joining AWS Partner Network
06/06/2024
Secures new life science company customer through this globally recognized and trusted new channel MINNEAPOLIS, June 06, 2024 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet” or the “Company”), the [...]
Breckenridge Distillery Wins Double Gold for a Consecutive Year in a Row at the 2024 New York International Spirits Competition
06/06/2024
The Distillery is Now a Four-Time Winner For ‘Colorado American Blended Whiskey Distillery Of The Year’ and its Signature Port Cask Finish Continues to Receive Praise BRECKENRIDGE, Colo., June 06, 2024 (GLOBE NEWSWIRE [...]
BridgeBio Pharma to Participate in the 45th Annual Goldman Sachs Global Healthcare Conference
06/06/2024
PALO ALTO, Calif., June 06, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today [...]
Venus Concept Regains Compliance with Nasdaq’s Minimum Equity Requirement
06/06/2024
TORONTO, June 06, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced that on June 4, 2024, it was notified by the [...]
4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Modulator-Ineligible/-Intolerant Cystic Fibrosis at 47th European Cystic Fibrosis Conference
06/06/2024
Clinically meaningful improvements in ppFEV 1 at 12 months observed in 2 of 3 participants with mild to moderate baseline lung function impairment (ppFEV 1 50-80%) and >6 months follow up Aerosolized 4D-710 was well [...]
Virbac : Declaration of the number of shares and voting rights 05/2024
06/06/2024
DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial [...]
Virbac : Déclaration d'actions et de droits de vote 05/2024
06/06/2024
DECLARATION D’ACTIONS ET DE DROITS DE VOTE Informations relatives au nombre total de droits de vote et au nombre d’actions composant le capital (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) [...]
Cartesian Therapeutics Announces New Employment Inducement Grant
06/06/2024
GAITHERSBURG, Md., June 06, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company developing mRNA cell therapies for the treatment of autoimmune [...]
Redecan Cannabis Introduces New Top Shelf Flower 'Purple Churro'
06/06/2024
The Tasty New Sativa Strain is Now Available Across Canada TORONTO, June 06, 2024 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), a leading global lifestyle and consumer packaged goods [...]
Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
06/06/2024
WAYNE, Pa., June 06, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today [...]
Replimune Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma
06/06/2024
Primary endpoint data shows 12-month overall response rate (ORR) of 33.6% Biologics license application (BLA) submission intended for 2H 2024; first patient expected to be enrolled in IGNYTE-3 confirmatory trial in Q3 [...]
Relay Therapeutics Discloses Three New Programs at New Program & Platform Event
06/06/2024
3 new programs include 2 genetic disease programs – vascular malformations & Fabry disease – & 1 precision oncology program – NRAS-specific inhibitor Cash guidance remains unchanged, and is expected to fund [...]
Chemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research Conference
06/06/2024
—Ex Vivo Studies Using Clinical Samples from Patients with Liver Fibrosis Reinforce the Anti-Fibrotic Activity of CM-101 by Showing the Drug’s Direct Interference with Liver Fibroblast Activation— — New Translational [...]
PetVivo Appoints Former NOVUS and Colgate-Palmolive Senior Sales & Marketing Executive, Bryan Monninger, as VP of Sales
06/06/2024
MINNEAPOLIS, MN, US, June 06, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTC: PETV, PETVW), a leading biomedical company delivering innovative therapeutic medical devices for equines and companion animals, has [...]
Castellum, Inc. Continues to Reduce Debt
06/06/2024
VIENNA, Va., June 06, 2024 (GLOBE NEWSWIRE) -- Castellum, Inc. (the "Company" or "Castellum") (NYSE-American: CTM) ($CTM), a cybersecurity, electronic warfare, and software services company focused on the federal [...]
U.S. National Institutes of Health Exercises Option to Fund $1.4 Million 2nd Year Budget for Pluri’s PLX-R18 Acute Radiation Syndrome Contract
06/06/2024
As part of Pluri’s previously announced $4.2 million 3-year contract with the U.S. National Institute of Allergy and Infectious Diseases (NIAID), the option for the second year of the contract has been exercise d to [...]

Pages